Ischemic Stroke
Conditions
Keywords
alteplase; urokinase; intravenous thrombolysis
Brief summary
To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China
Detailed description
Compare the efficacy and safety of different thrombolytic drugs; Analysis of patients during hospital treatment of adverse events and complications; Analysis of factors that affect the effectiveness of treatment; Evaluate the pharmacological benefits of different thrombolytic drugs
Interventions
DRUGAlteplase
According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
DRUGUrokinase
1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
Sponsors
General Hospital of Shenyang Military Region
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 1\) age\> 18 years old; * 2\) meet the diagnostic criteria of China 2014 guidelines for the diagnosis and treatment of acute ischemic stroke; * 3\) no history of first sepsis or previous cerebral infarction sequelae (mRS ≤ 1); * 4\) within 3 hours of onset; * 5\) Have measurable neurological deficits; * 6\) Patients or legal guardians can understand and sign informed consent.
Exclusion criteria
* Absolute
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mRS of 90 days after thrombolysis | Month 3 | Proportion of patients with mRS = 0-1 points 90 days after thrombolysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of Adverse events | Year 1 | Symptomatic intracranial hemorrhage conversion rate; Liver and kidney dysfunction; Bleeding gums; Skin mucous membrane bleeding |
Other
| Measure | Time frame | Description |
|---|---|---|
| Economic evaluation | Day 14 | The cost-effectiveness of different thrombolytic drugs |
Countries
China
Outcome results
None listed